Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
34 Results for "
Pyruvate Kinase M2
" in MedChemExpress (MCE) Product Catalog:
Products (34)
34 Results for "Pyruvate Kinase M2" in MCE Product Catalog:
74
74 Publications Verification
Synonyms: C.I. 75535; Isoarnebin 4
56
Target:
Research Areas:
TEPP-46 (ML-265) is a potent and selective pyruvate kinase M2 (PKM2) activator with an AC50 of 92 nM, showing little or no effect on PKM1, PKL and PKR .
30
30 Cited Publications
Target:
Research Areas:
PKM2-IN-1 (compound 3k) is a pyruvate kinase M2 (PKM2) inhibitor with an IC50 of 2.95 μM .
4
Category:
Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields Cancer
Target:
2
2 Cited Publications
Cat. No.: HY-P80870
Synonyms: PKM; OIP3; PK2; PK3; PKM2; Pyruvate Kinase isozymes M1/M2; Cytosolic thyroid hormone-binding protein; CTHBP; Opa-interacting protein 3; OIP-3; Pyruvate Kinase 2/3; Pyruvate Kinase muscle isozyme; Thyroid hormone-binding protein 1; THBP1; Tu
1
1 Cited Publications
Cat. No.: HY-P7803
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PKM; Tumor M2-PK; Prev. PKM2; P58; THBP1; Thyroid Hormone-Binding Protein, Cytosolic; OIP3; Epididymis Secretory Protein Li 30; PK3; Pyruvate Kinase Isozymes M1/M2; Pyruvate Kinase Muscle Isozyme; OPA-Interacting Protein 3; Cytosolic Thyroid Hormone-Bindi
Species:
Human
Source:
E. coli
Target:
Research Areas:
PKM2 activator 2 (compound 28) is a pyruvate kinase M2 (PKM2) activitor with an AC50 value of 66 nM. PKM2 activator 2 can restore normal glycolytic metabolism in cells .
Target:
Pyruvate Kinase COX STAT TNF Receptor NO Synthase Interleukin Related HIF/HIF Prolyl-Hydroxylase
Research Areas:
Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases .
Cat. No.: HY-119874
CAS No.: 23444-65-7
Category:
Quinones Ohwia caudata (Thunberg) H. Ohashi Monophenols Phenols Plants Compositae Extract Disease Research Fields Inflammation/Immunology Naphthalene Quinones
Target:
Cat. No.: HY-111936
CAS No.: 562867-96-3
Synonyms: BML283
Target:
Research Areas:
ML083 is a member of a series of highly specific allosteric activators for the tumor-specific isoform of human pyruvate kinase (M2 isoform). ML083 affects the cooperativity of phosphoenolpyruvate (PEP) binding. ML083 can be used in the research of tumors .
Cat. No.: HY-126585S
Cat. No.: HY-170577
CAS No.: 3115004-02-6
Target:
Research Areas:
PKM2-IN-8 (Compound 9b) is a pyruvate kinase M2 (PKM2) inhibitor (IC50 = 0.31 μM). PKM2-IN-8 has potent antiproliferative activity against U87MG glioma cells. PKM2-IN-8 can induce early apoptosis and reduce lactate levels. PKM2-IN-8 can be used for the research of glioblastoma .
Cat. No.: HY-178441
Research Areas:
PKM2-IN-11 is a PKM2 inhibitor (IC50 = 0.363 μM). PKM2-IN-11 has dual mechanisms involving pyruvate kinase M2 (PKM2) inhibition and microtubule stabilization. PKM2-IN-11 can decrease PKM2 protein levels in MCF-7 cells. PKM2-IN-11 can slightly reduce reactive oxygen species (ROS) levels and significantly increase early apoptotic cells. PKM2-IN-11 induces G2/M phase arrest. PKM2-IN-11 can be used for the study of breast cancer .
Target:
Research Areas:
ML202 is a highly specific allosteric activator of human pyruvate kinase M2 (hPK-M2), which can affect the cooperativity of phosphoenolpyruvate (PEP) binding, while adenosine diphosphate (ADP) binding almost no effect .
Cat. No.: HY-162071
CAS No.: 904457-46-1
Target:
Research Areas:
PKM2-IN-5 (Compound G1) is an inhibitor for pyruvate kinase M2 (PKM2), with IC50 >70 μM .
Cat. No.: HY-W753956
CAS No.: 3044090-39-0
Cat. No.: HY-110124R
CAS No.: 1221186-52-2
Target:
Research Areas:
ML202 (Standard) is the analytical standard of ML202 (HY-110124). This product is intended for research and analytical applications. ML202 is a highly specific allosteric activator of human pyruvate Kinase M2 (hPK-M2), which can affect the cooperativity of phosphoenolpyruvate (PEP) binding, while adenosine diphosphate (ADP) binding almost no effect .
Cat. No.: HY-P83644
Synonyms: PKM2 (Phospho Tyr105); PKM2 (Phospho Y105); PK 1; PK 2; PK 3; PK Muscle type; PK1; PK2; Pk3; PKL; PKLR; PKM 2; PKM; PYKM; Pyruvate Kinase 1; Pyruvate Kinase 2/3; Pyruvate Kinase 3; Pyruvate Kinase isozyme R/L; Pyruvate Kinase isozymes M1/M2; Pyruvate Kinase liver and blood cell; Pyruvate Kinase liver and RBC; Pyruvate Kinase liver and RBC type; Pyruvate Kinase M2; Pyruvate Kinase muscle; Pyruvate Kinase muscle isozyme; Pyruvate Kinase type L; R type/L type Pyruvate Kinase; Red cell/liver Pyruvate Kinase; RPK; TCB; THBP 1; THBP1; Thyroid hormone binding protein cytosolic; CTHBP; Cytosolic thyroid hormone binding protein; MGC3932; OIP 3; Oip3; Tumor M2-PK; p58; OIP-3.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
